Financial Performance - The company's operating revenue for Q3 2024 was ¥105,425,203.18, a decrease of 1.50% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥42,853,556.48, down 15.24% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,850,843.89, a decrease of 14.08% compared to the previous year[2] - Basic earnings per share for Q3 2024 were ¥0.31, down 26.19% from the same period last year[3] - Net profit for Q3 2024 was approximately ¥161.67 million, down from ¥168.53 million in Q3 2023, indicating a decrease of about 4.3%[15] - Basic and diluted earnings per share for Q3 2024 were both ¥1.28, compared to ¥1.40 in Q3 2023, showing a decline of approximately 8.6%[15] - The total profit for Q3 2024 was approximately ¥188.77 million, down from ¥197.26 million in Q3 2023, reflecting a decrease of about 4.5%[14] Cash Flow - Cash flow from operating activities for the period was ¥65,864,008.27, a decline of 17.63% year-on-year[2] - Cash flow from operating activities for the first three quarters of 2024 was approximately ¥167.67 million, an increase from ¥152.84 million in the same period of 2023[16] - The company’s total cash outflow from operating activities was approximately ¥240.89 million in the first three quarters of 2024, down from ¥255.67 million in the same period of 2023[16] - Total cash inflow from investment activities amounted to ¥5,989,655.70, compared to ¥3,349,205.82 in the previous year[17] - Cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was ¥67,508,531.14, up from ¥59,637,804.33 year-over-year[17] - Net cash flow from investment activities was negative at ¥361,518,875.44, compared to a negative ¥104,288,598.51 in the same period last year[17] - Total cash inflow from financing activities reached ¥473,683,876.81, significantly higher than ¥1,975,439.00 in the previous year[17] - Net cash flow from financing activities was positive at ¥463,327,854.95, compared to a negative ¥2,044,256.47 last year[17] - The net increase in cash and cash equivalents was ¥269,477,943.69, compared to an increase of ¥46,502,204.67 in the previous year[17] - The ending balance of cash and cash equivalents stood at ¥552,013,365.43, compared to ¥105,163,858.95 at the end of the previous year[17] Assets and Equity - The total assets at the end of the reporting period were ¥1,351,335,761.62, an increase of 89.62% compared to the end of the previous year[3] - The equity attributable to shareholders at the end of the reporting period was ¥1,190,435,053.69, reflecting a growth of 105.26% year-on-year[3] - As of September 30, 2024, total assets amounted to RMB 1,351,335,761.62, compared to RMB 712,650,946.12 at the end of 2023, indicating a significant increase of approximately 89.9%[12] - Current assets totaled RMB 998,784,898.40 as of September 30, 2024, up from RMB 452,062,918.80 at the end of 2023, representing an increase of approximately 121.5%[10] - The company's equity attributable to shareholders reached RMB 1,190,435,053.69, up from RMB 579,954,207.64 at the end of 2023, reflecting an increase of approximately 105.2%[12] Operating Costs and Expenses - Total operating costs increased to approximately ¥179.22 million from ¥174.33 million year-over-year, with operating costs specifically rising to ¥125.38 million from ¥125.11 million[14] - The company reported a decrease in sales expenses to approximately ¥30.18 million from ¥28.15 million year-over-year, indicating a rise of about 7.3%[14] - Research and development expenses for Q3 2024 were approximately ¥10.67 million, compared to ¥7.82 million in Q3 2023, marking an increase of about 36.9%[14] Government Subsidies and IPO - The company received government subsidies amounting to ¥3,214.29 during the reporting period, contributing to non-recurring gains[4] - The company completed its initial public offering in August 2024, which significantly boosted its total assets and equity[5] Accounts and Inventory - Accounts receivable increased to RMB 95,190,798.19 from RMB 85,390,872.81, indicating a growth of approximately 11.1%[10] - Inventory decreased to RMB 41,566,870.34 from RMB 49,902,888.53, representing a decline of approximately 16.6%[11] - The company reported a decrease in other current assets to RMB 1,359,059.32 from RMB 16,882,795.01, a reduction of approximately 91.9%[10] Shareholder Participation - The company has not reported any significant changes in shareholder participation in financing or margin trading activities during the reporting period[9]
小方制药(603207) - 2024 Q3 - 季度财报